A Phase 3 interventional study of Pioglitazone and Placebo in Mild Cognitive Impairment Due to Alzheimer's Disease, sponsored by Takeda. Terminated at 43 sites in 4 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-07-02.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,039th largest by enrollment of the 1,609 interventional ones that give a count, is one of 72 that started in 2015, is one of 188 in phase 3, and was the 667th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 72 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 7 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).
The drug being tested in this study is called pioglitazone. This study is designed to further evaluate the safety and effectiveness of pioglitazone on cognitive function in participants who have completed the AD-4833/TOMM40_301. This study will look at the effectiveness of pioglitazone on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study with a diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).
The study enrolled 40 participants, but is dependent on how many decide to continue treatment in an extension phase after completing the main (301) study. Participants will continue to receive the same study medication they received during the pivotal AD-4833/TOMM40_301 study, either:
All participants will be asked to take one tablet at the same time each day throughout the study.
This multi-centre trial, like its precedent pivotal trial, will be conducted worldwide. The overall time to participate in this study is minimum 2 years and a maximum of 7 years depending on when participants roll over from the 301 study. Participants will make approximately 2 visits per year to the clinic, and will be contacted by telephone 3 months after each treatment visit for a follow-up assessment, and 2 weeks after the final visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Had any of the following values at the extension study Baseline Visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
Drug: Pioglitazone
Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
Drug: Placebo
Pioglitazone tablets
Also known as: AD-4833
Pioglitazone placebo-matching tablets
Change From Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery at Month 24
Composite scores were derived from the test battery. Each test in the battery falls into 1 of the following cognitive domains: Episodic Memory (California Verbal Learning Test - 2nd Edition \[CVLT-II\], Brief Visuospatial Memory Test - Revised \[BVMT-R\]), Executive Function (Trail Making Part B, Digit Span Backwards), Language (Animals, Lexical/Phonemic Fluency), Attention (Digit Span Forward, Trail Making Part A), and Visuospatial (Clock Drawing, BVMT-Copy). Only the domains of episodic memory, executive function, language, and attention were used for the calculation of composite score (i.e., Clock Drawing, BVMT-Copy, and the Multilingual Naming Test (MINT), which do not allow generation of standard z scores, were only used for diagnostic purposes and were excluded from the calculation of the composite score). To form the composite, z-scores were calculated for each test, each z-score for the domain were averaged, and then all relevant domains were averaged to form the composite.
Time frame: Baseline and Month 24
Time to Diagnosis of Alzheimer's Disease (AD) Dementia
Time frame: Day 1 and every 6 months (up to maximum of 36 months)
Participants took part in the study at 3 investigative sites in Australia, United Kingdom and United States from 12 Feb 2015 to 08 May 2018.
| Milestone | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone |
|---|---|---|---|
| Started | 3 | 18 | 19 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 18 | 19 |
| Withdrew: Pretreatment event/adverse event | 0 | 1 | 0 |
| Withdrew: Major protocol deviation | 0 | 1 | 0 |
| Withdrew: Voluntary withdrawal | 2 | 4 | 5 |
| Withdrew: Study termination | 0 | 11 | 14 |
| Withdrew: Reason not specified | 1 | 1 | 0 |
Composite scores were derived from the test battery. Each test in the battery falls into 1 of the following cognitive domains: Episodic Memory (California Verbal Learning Test - 2nd Edition \[CVLT-II\], Brief Visuospatial Memory Test - Revised \[BVMT-R\]), Executive Function (Trail Making Part B, Digit Span Backwards), Language (Animals, Lexical/Phonemic Fluency), Attention (Digit Span Forward, Trail Making Part A), and Visuospatial (Clock Drawing, BVMT-Copy). Only the domains of episodic memory, executive function, language, and attention were used for the calculation of composite score (i.e., Clock Drawing, BVMT-Copy, and the Multilingual Naming Test (MINT), which do not allow generation of standard z scores, were only used for diagnostic purposes and were excluded from the calculation of the composite score). To form the composite, z-scores were calculated for each test, each z-score for the domain were averaged, and then all relevant domains were averaged to form the composite.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Up to 30 days after receiving the last dose of study drug (approximately up to 1113 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Risk Placebo | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| High Risk Placebo | 0/18 (0%) | 4/18 (22.2%) | 10/18 (55.6%) |
| High Risk Pioglitazone | 0/19 (0%) | 3/19 (15.8%) | 12/19 (63.2%) |
| Event | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/3 | 1/18 | 0/19 |
| Myocardial infarctionCardiac disorders | 0/3 | 1/18 | 0/19 |
| Non-cardiac chest painGeneral disorders | 0/3 | 1/18 | 0/19 |
| LacerationInjury, poisoning and procedural complications | 0/3 | 1/18 | 0/19 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 1/18 | 0/19 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/18 | 0/19 |
| Retinal artery occlusionEye disorders | 0/3 | 0/18 | 1/19 |
| Femur fractureInjury, poisoning and procedural complications | 0/3 | 0/18 | 1/19 |
| Hip fractureInjury, poisoning and procedural complications | 0/3 | 0/18 | 1/19 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/3 | 0/18 | 1/19 |
| Event | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/18 | 0/19 |
| Dementia Alzheimer's typeNervous system disorders | 1/3 | 0/18 | 0/19 |
| Upper respiratory tract infectionInfections and infestations | 0/3 | 2/18 | 4/19 |
| Urinary tract infectionInfections and infestations | 0/3 | 2/18 | 1/19 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 2/18 | 0/19 |
| CataractEye disorders | 0/3 | 0/18 | 2/19 |
| FallInjury, poisoning and procedural complications | 0/3 | 1/18 | 2/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/18 | 2/19 |
| Pancreatic cystGastrointestinal disorders | 0/3 | 1/18 | 0/19 |
| ContusionInjury, poisoning and procedural complications | 0/3 | 1/18 | 0/19 |
Safety analysis set included all participants who received at least 1 dose of blinded study medication.
| Age, Continuous(years) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| Mean | 74.7 ± 4.73 | 78.9 ± 3.98 | 78.1 ± 4.42 | 78.2 ± 4.27 |
| Sex: Female, Male(Participants) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| Female | 1 | 5 | 10 | 16 |
| Male | 2 | 13 | 9 | 24 |
| Race/Ethnicity, Customized(Participants) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 3 |
| Not Hispanic or Latino | 2 | 17 | 18 | 37 |
| Race/Ethnicity, Customized(Participants) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| Black or African American | 0 | 0 | 1 | 1 |
| White | 3 | 18 | 18 | 39 |
| Race/Ethnicity, Customized(Participants) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| Non-Hispanic/Latino Caucasian | 2 | 17 | 17 | 36 |
| Hispanic/Latino and/or non-Caucasian | 1 | 1 | 2 | 4 |
| Region of Enrollment(Participants) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| United States | 2 | 11 | 15 | 28 |
| United Kingdom | 1 | 2 | 2 | 5 |
| Australia | 0 | 5 | 2 | 7 |
| Height(cm) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| Mean | 169.7 ± 4.16 | 168.7 ± 10.85 | 166.8 ± 11.73 | 167.9 ± 10.81 |
| Weight(kg) | Low Risk Placebo | High Risk Placebo | High Risk Pioglitazone | Total |
|---|---|---|---|---|
| Mean | 78.20 ± 6.053 | 76.00 ± 13.719 | 72.11 ± 15.685 | 74.32 ± 14.224 |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Feb 2015 to primary completion in Jan 2018, 35 months.
Results were first posted in Jul 2019, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pioglitazone